Iranian WhartoCell medicine for osteoarthritis treatment receives IFDA authorization

Tehran, IRNA – WhartoCell, an Iranian knowledge-based medicine, developed from umbilical cord–derived stem cells, has entered clinical therapy after receiving authorization from Iran Food and Drug Administration (IFDA), a government regulatory body.